Roche Reports 7% Q1 Sales Increase, Confirms FY25 Outlook

Roche reported a 7% rise in first-quarter sales to 15.44 billion Swiss francs, slightly surpassing analysts’ expectations, driven by strong demand for newer medicines such as Phesgo for breast cancer, Vabysmo for severe eye diseases, Xolair for allergies, and Hemlibra for haemophilia A. The Pharmaceuticals Division saw a 9% sales increase, while sales in the Diagnostics Division remained stable. Roche confirmed its full-year outlook, projecting a mid single-digit percentage increase in group sales and a high single-digit rise in core earnings per share at constant currency rates. The company also reiterated plans to continue increasing its dividend. Management expressed confidence in maintaining positive momentum amid anticipation for upcoming clinical trial results that could shape future growth.